-
Ultimovacs ASA: Mandatory notification of trades by primary insider
-
Ultimovacs ASA: Mandatory notification of trades by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insiders
-
Ultimovacs ASA: Mandatory notification of trade by primary insiders
-
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
-
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
-
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
-
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
-
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
-
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
